Skip navigation.

Sponsored by

Primate testing in Europe

References

1 Nielsen R. et al. (2005), A Scan for positively selected genes in the genomes of humans and chimpanzees PLoS Biology, June; 3(6): e 170
2 Report A5-0387/2002 adopted 13.11.2002
3 www.ad-international.org
4 http://212.3.246.100/Objects/2/Files/ReviewDirective
86609final.doc
5 http://www.nc3rs.org.uk/downloaddoc.asp?id=322
6 http://ec.europa.eu/enterprise/pharmaceuticals/eu
dralex/vol-1/dir_2001_83_cons/dir2001_83_cons_en.pdf
7 Smith, D. and Trennery, P. (2002) “Non-rodent Selection in Pharmaceutical Toxicology; A ‘Points to Consider’ document, developed by the ABPI in conjunction with the UK Home Office”
8 http://www.nc3rs.org.uk/downloaddoc.asp?id=515&
page=207&skin=0
9 Lin, J.H. & Lu, A.Y.H. (1997) “Role of pharmacokinetics and metabolism in drug discovery and development” Pharmacological Reviews, vol. 49, no.4, pp.403-449
10 Ward, K.W. & Smith, B.R. (2004) ”A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance”, Drug metabolism and disposition, vol.32, no.6, pp.603-611
11 Takahashi, M. et al (2007) “Characterization of gastrointestinal drug absorption in cynomolgus monkeys”, Molecular Pharmaceutics, vol.5, no.2, pp.340-348.
12 Lin, J.H. (1998) “Applications and limitations of interspecies scaling and in vitro extrapolation in pharmacokinetics” Drug metabolism and Disposition, vol.26, no.12, pp.1202-1212
13 Chiou, W.L. & Buehler, P.W. (2002) “Comparison of oral absorption and bioavailability of drugs between monkey and human”, Pharmaceutical Research, vol. 19, no. 6, pp.868-874
14 Uno, Y et al (2006) “CYP2C76, a novel cytochrome P450 in cynomolgus monkey, is a major CYP2C in liver, metabolizing tolbutamide and testosterone”, Molecular Pharmacology, vol.70, no.2, pp. 477-486.
15 Uno, Y. et al (2007) “Characterization of cynomolgus monkey cytochrome P450 (CYP) cDNAs: Is CYP2C76 the only monkey-specific CYP gene responsible for species differences in drug metabolism” , Archives of Biochemistry and Biophysics, vol.466, pp.98-105
16 Nishimura, M. et al (2007) “Comparison of Inducibility of CYP1A and CYP3A mRNAs by prototypical inducers in primary cultures of human, cynomolgus monkey and rat hepatocytes”, Drug metabolism and Pharmacokinetics, vol. 22, no.3, pp.178-186
17 Caldwell, J. (1992). Species differences in metabolism and their toxicological significance, Toxicol. Lett. 64, 106
18 House of Lords Select Committee on Animals in Scientific Procedures (2002). HL150-I, 16 July
19 Palfreyman, M. G., Charles, V. and Blander, J. (2002). The importance of using human-based models in gene and drug discovery, Drug Discovery World, 33–40, [Personal communication from professional statistician]
20 Contemporaneous Notes 06
21 Contemporaneous Notes 06; Investigator, laboratory questionnaire 08
22 UK Home Office, January 2003, www.navs.org.uk
23 The Animal Defender and Campaigner Magazine, Autumn-Winter 2005, p.44
24 Contemporaneous Notes 07
25 Contemporaneous Notes 08
26 Contemporaneous Notes 07
27 Contemporaneous Notes 07
28 Contemporaneous Notes Suppliers log
29 Prescott, MJ & Jennings, M (2004) “Ethical and welfare implications of the acquisition and transport of non-human primates for use in research and testing” ATLA, vol 32, suppl.1, pp.323-327
30 Wolfensohn, S.E. (1997) “Brief review of scientific studies of the welfare implications of transporting primates”, Laboratory Animals, vol.31, pp.303-305
31 Contemporaneous Notes Suppliers
32 Investigator, written answers 08
33 Contemporaneous Notes Suppliers 07
34 Contemporaneous Notes 07
35 Contemporaneous Notes 07
36 Contemporaneous Notes Suppliers 07
37 Contemporaneous Notes Suppliers 07
38 Contemporaneous Notes Suppliers
39 Contemporaneous Notes 08
40 The Animal Procedures Committee, (February 2006) “Acceptance of Overseas centres supplying Non-human Primates to UK laboratories: A report by the primates sub-committee of the Animals Procedures Committee”
41 The Animal Procedures Committee, (2007) “Consideration of policy concerning standards of animal housing and husbandry for animals from overseas non-designated sources”
42 http://scienceandresearch.homeoffice.gov.uk/animal-research/publications-and-reference/publications/reports-and-reviews/annual-report05
43 http://coombs.anu.edu.au/~vern/wild-trade/docs/ducippl96.txt – accessed 27/10/08
44 http://www.parliament.the-stationery-office.co.uk/pa/cm200607/cmhansrd/cm070122/text/70122w0019.htm
45 http://www.parliament.the-stationery-office.com/pa/cm200607/cmhansrd/cm061123/text/61123w0016.htm
46 http://www.homeoffice.gov.uk/about-us/freedom-of-information/released-information/foi-archive-research1/4999-non-human-primates-overseas?view=Html – accessed 24/10/08
47 http://www.parliament.the-stationery-office.co.uk/pa/cm200607/cmhansrd/cm070122/text/70122w0019.htm
48 Investigator, laboratory questionnaire 06
49 Investigator, laboratory questionnaire 06
50 Investigator, laboratory questionnaire 08
51 Contemporaneous Notes 08
52 Investigator, husbandry questionnaire 08
53 Paper 4,”Welfare considerations in the use of macaques and marmosets”, Boyd Group papers on the use of non-human primates in research and testing, June 2002
54 Abney, D. et al (2006) “Human-animal relationship in the research lab: a discussion by the refinement and enrichment forum”, Animal Technology and Welfare, August, pp.95-98
55 http://www.nature.org/wherewework/asiapacific/ind
onesia/features/fishingmonkey.html – accessed 22/12/08
56 International Primatological Society (Captive Care Committee) (2007) IPS International guidelines for the acquisition, care and breeding of Non human primates – 2nd Edition
57 Investigator, written answers 08
58 Lutz, C.K. & Novak, M.A (2005) “Environmental enrichment for non-human Primates: Theory and application” ILAR Journal, vol. 46, no.2 pp.178-191
59 Reinhardt, V. and Roberts, A. (1997) “Effective feeding enrichment for non-human primates: A brief review” Animal Welfare, vol.6, pp.265-272
60 Boccia, M.L. et al (1995) “Individual differences in Macaques’ responses to stressors based on social and physiological factors: implications for primate welfare and research outcomes” Laboratory Animals vol. 29, pp.250-257
61 Contemporaneous Notes 07
62 “Working safely with simians: Management of infection risks. Specialist supplement To: Working safely with research animals: Management of infection risks (1998) HSE Books
63 Contemporaneous Notes 07
64 Contemporaneous Notes 07
65 Contemporaneous Notes 07
66 Contemporaneous Notes 07
67 “Welfare considerations in the use of macaques and, marmosets” Boyd Group papers on the use of non-human primates in research and testing June 2002
68 Contemporaneous Notes 07
69 Contemporaneous Notes 07
70 Contemporaneous Notes 07
71 Contemporaneous Notes 07
72 Contemporaneous Notes 07
73 Investigator, Medical Log 07
74 http://www.gsk.com/investors/reps07/annual-report-2007.pdf
75 Contemporaneous Notes 07
76 Contemporaneous Notes 09
77 Prates, H. M and Bicca-Marques, J. C (2005) “Coprophagy in Captive Brown Capuchin Monkeys (Cebus Apella)” Neotropical Primates vol.13, no.3, pp: 18-21
78 Wolfensohn, S and Honess, P (2005) Handbook of Primate Husbandry and Welfare Blackwell Publishing, UK
79 Contemporaneous Notes 07
80 Contemporaneous Notes 07
81 Investigator, written answers 08
82 Investigator, written answers 08
83 Investigator, written answers 08
84 Investigator, written answers 08
85 Investigator, written answers 08
86 Investigator, written answers 08
87 Investigator, written answers 08
88 Investigator, written answers 08
89 Investigator, Medical Log 08
90 Investigator, Medical Log 08
91 Investigator, written answers 08
92 Investigator, Medical Log 08
93 Contemporaneous Notes 08
94 Contemporaneous Notes 08
95 Contemporaneous Notes 08
96 Contemporaneous Notes 08
97 Investigator, written answers 08
98 Contemporaneous Notes 08
99 Contemporaneous Notes 08
100 Contemporaneous Notes 08
101 Contemporaneous Notes 08
102 Contemporaneous Notes 08
103 Contemporaneous Notes 08
104 Investigator, Medical Log 08
105 Contemporaneous Notes 08
106 Contemporaneous Notes 08
107 Contemporaneous Notes 08
108 Contemporaneous Notes 08
109 Contemporaneous Notes 08
110 Special Notes on animal 205050548
111 Contemporaneous Notes 07
112 Contemporaneous Notes 07
113 Investigator, Medical Log 07
114 Contemporaneous Notes 07
115 Contemporaneous Notes 07
116 Contemporaneous Notes 07
117 Reinhardt, V (1994) “Traditional Handling Procedures of Laboratory Non-human Primates are an Intrinsic source of Distress: What can be done?” http://www.awionline.org/Lab_animals/biblio/tou-hand.htm – accessed 09/07/08
118 Contemporaneous Notes 07
119 Video: 04.12.07
120 Seier, J.V. et al (2008) “Voluntary consumption of substances of unknown palatability by vervet monkeys: a refinement” Journal of medical Primatology, vol. 37, pp. 88-92
121 Reinhardt, V. (2003) “Working with rather than against macaques during blood collection”, Journal of Applied Animal Welfare Science, vol.6 (3) pp.189-197
122 Prescott, M.J. & Buchanan-Smith, H.M. (2007) “Training laboratory-housed non-human primates, part 1; a UK survey”, Animal Welfare, vol.16, pp.21-36
123 Contemporaneous Notes 08
124 Investigator, Medical Log 07
125 http://www.med.nyu.edu/dlar/assets/environment.pdf – accessed 21/09/08
126 Wolfensohn, S.E & Lloyd, M (1998) Introduction to the Principles of Animal Care and Use, in “Handbook of Laboratory Animal Management and Welfare”, 2nd Edition, Blackwell Science
127 O’Neill, P (1989) “A room with a view for captive primates: Issues, goals, related research and strategies” in Housing, Care and Psychological well-being of captive and laboratory primates, editor. E.F. Segal
128 Contemporaneous Notes 07
129 Contemporaneous Notes 07
130 Contemporaneous Notes 07
131 Contemporaneous Notes 07
132 Contemporaneous Notes 07
133 Contemporaneous Notes 07
134 Investigator, welfare log 07
135 Contemporaneous Notes 07
136 Contemporaneous Notes 07
137 Contemporaneous Notes 07
138 Investigator, welfare log 07
139 Investigator, welfare log 07
140 Investigator, welfare log 07
141 Guidance on the Operation of the Animals (Scientific Procedures) Act 1986 http://www.archive.official-documents.co.uk/document/hoc/321/321-05.htm
142 Video, 06.11.07
143 Contemporaneous Notes 06
144 Contemporaneous Notes, Study Report: BV0963
145 Contemporaneous Notes, Study Report: JLY0129
146 Contemporaneous Notes, Study Report: KSI0160
147 Contemporaneous Notes 07
148 Contemporaneous Notes 07
149 Wolfensohn, S & Lloyd, M (1998), in ‘Handbook of Laboratory Animal Management and Welfare’. Blackwell Science, Oxford
150 “Key considerations in the breeding of macaques and marmosets for scientific purposes” Laboratory Animal Science Association and the Medical research Council, May 2004
151 Contemporaneous Notes: Study Report CPB0014
152 Contemporaneous Notes 07
153 Contemporaneous Notes: Study Report BAX0011
154 Contemporaneous Notes 07
155 Ruys. J.D. et al (2004) “Behavioral and physiological adaptation to repeated chair restraint in rhesus macaques”, Physiology & Behavior, vol. 82, pp.205-213
156 Contemporaneous Notes: Study Report BAX0011
157 Kessler, RH (1967), in: Drug Responses in Man. Eds Wolstenholme, G., Porter, RJ & Churchill, A, Ltd., London, pp130-131
158 Appleby, E.C., (1961). Virus in Monkeys – A Warning. The Veterinary Record, Vol: 73, pp: 41.
159 Palfreyman, M. G., Charles, V. and Blander, J. (2002). The importance of using human-based models in gene and drug discovery, Drug Discovery World, 33–40, [Personal communication from professional statistician].
160 Brodies, B.B. Ibid. pp: 197).
161 SCRIP Magazine, November 1998: 6-7
162 The Campaigner, July-December 1997: 47 / SCRIP 1998
163 SCRIP 2429, 16 April 1999: 26
164 SCRIP 2724, 27 February 2002
165 SCRIP 2726, 6 March 2002: 23
166 Liverpool Daily Post, 7 June 2001: 18
167 Turner, P (1988). Clinical Pharmacology 11 (Suppl.1): S113-S120
168 Gosling, W.R.O. In: Drug Responses in Man. 1967. Eds; Wolstenholme, G., Porter, R.J. & Churchill, A., Ltd., London, pp: 178
169 Welch, A.D. In: Drug Responses in Man. 1967. Eds; Wolstenholme, G., Porter, R.J. & Churchill, A., Ltd., London, pp: 6.
170 ADI, The failed trial of TGN1412, Animal Defender, p8-9
171 LDF 2008, Microdosing fast forward, New Science, p4
172 Contemporaneous Notes, Study Report BVR0963
173 Noble, S (2004) “Therapeutic AIDS vaccines: Are they feasible and is their development a separate endeavor from preventative vaccines?” IAVI Report vol.7, no.3, pp.225-232
174 NIH Report: “Assessment of Adenoviral Vector Safety and Toxicity: Report of the National Institutes of Health Recombinant DNA Advisory Committee.” (2002) Human Gene Therapy vol.13, pp.3-13
175 Casimiro, D. R et al (2005) “Attenuation of Simian Immunodeficiency Virus SIVmac239 Infection by Prophylactic Immunization with DNA Recombinant Adenoviral; Vaccine Vectors Expressing Gag.” Journal of Virology vol.79, no.24, pp.15547-15555
176 Watkins, D I et al (2008) “Non-human primate models and the failure of the Merck HIV-1 vaccine in humans.” Nature Medicine vol.14, no.6, pp.617-621
177 Van Gall, L F et al (2008) “Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonist or insulin for patients with inadequate glycemic control?” European Journal of Endocrinology vol.158, pp.773-784
178 Edwards, C M B, et al (1999) “Glucagon-Like Peptide 1 Has a Physiological Role in the Control of Postprandial Glucose in humans. Studies With the Antagonist Exendin 9-39.” Diabetes vol.48, pp.86-93.
179 Triplitt, C et al (2007) “The Changing Landscape of Type 2 Diabetes: The Role of Incretin-Based Therapies in Managed Care Outcomes.” Journal of Managed Care Pharmacy vol.134, no.9, S-c
180 Farilla, L et al (2003) “Glucagon-Like Peptide 1 Inhibits Cell Apoptosis and Improves Glucose Responsiveness of Freshly Isolated Human Islets.” Endocrinology vol.144, no.12, pp.5149-5158
181 Takeda, H. et al (2002) “Characterization of β- Adrenoceptor subtype in bladder smooth muscle in cynomolgus monkey”,Japanese Journal of Pharmacology, vol.88,pp.103-113
182 Andersson, K.E. (1999) “Physiological society symposium: The physiology and pathophysiology of the lower urinary tract – Advances in the pharmacological control of the bladder”, Experimental Physiology, vol.84,pp.195-213
183 “A growing sense of urgency – new incontinence drugs must distinguish themselves”, Pharmaceutical & Diagnostic innovation, vol.2, no.3, pp.13-16
184 Contemporaneous Notes, Study Report CPB0014
185 Koskinen, K. et al (2004)”Granulocyte transmigration through the endothelium is regulated by the oxidase activity of vascular adhesion protein-1 (VAP-1)
186 http://www.biotie.com/WebRoot/1009506/Stock
NewsDetails.aspx?id=1013836&NewsItemID=1241940&NewsItemYear=2008
187 http://www.nc3rs.org.uk/downloaddoc.asp?id=515&
page=207&skin=0 accessed 20/12/08 same as 8 but 8 has no date
188 Chapman, K. et al (2007) “Preclinical safety testing of monoclonal antibodies: the significance of species relevance” Nature drug Discovery, vol.6,pp. 120-126
189 Mannucci, P.M. (2001) “How I treat patients with von Willebrand disease” Blood, 1st April, vol.97, no.7.pp.1915-1919
190 http://www.cinn=cinnatichildrens.org/health/info/
blood/diagnose/von-willebrand.htm -accessed 07/07/08
191 Fischer, B.E. (1999) “Recombinant von Willebrand Factor: Potential Therapeutic Use” Journal of Thrombosis and Thrombolysis, vol.8, pp.197-205
192 Muller, D.P.R (1987) “Free radical problems of the newborn” Proceedings of the Nutrition Society, vol. 46, pp.69-75
193 Patterson, M.M. et al (2002) “Type -3 von Willebrand’s disease in a rhesus monkey (Macaca mulatta)”, Comparative Medicine, vol.52, no.4, pp.368-370)
194 http://www.baxter.com/about_baxter/news_room/
news_releases/2006/12-11-06-von_willebrand_factor.html
195 Stadler, M. et al (2006) “Characterisation of a novel high-purity, double virus inactivated von Willebrand Factor and Factor VIII concentrate (Wilate ®)”, Biologicals, vol. 34, pp.281-288
196 Denis, C.V. & Wagner, D.D. (1999) “Insights from von Willebrand disease animal models”, Cellular and Molecular Life Sciences, vol56, pp.977-990
197 Mannucci P.M. et al (2001) “Treatment of von Willebrand disease with a high purity factor VIII / von Willebrand factor concentrate: a prospective, multicenter study”, Blood, vol. 99, no.2. pp.450-456
198 Vedani, A. et al (2007)”Predicting the Toxic Potential of Drugs and Chemicals In Silico”, ALTEX,24, Special Issue, pp.63-66
199 http://www.emea.europa.eu/pdfs/human/swp/
259902en.pdf
200 http://www.xceleron.com/metadot/index.pl?iid=2494
201 Rowland, M (2006) Microdosing and the 3Rs, NC3Rs #5
202 http://www.xceleron.com/metadot/index.pl?iid=
2382&isa=Newsitem&op=show
203 http://www.xceleron.com/metadot/index.pl?id=
2752&isa=DBRow&op=show&dbview_id=2596
204 The Pharmaceutical Journal, vol. 273, pp.528
205 Sarapa, N. (2003) “Early human microdosing to reduce attrition in clinical drug development”, American Pharmaceutical Outsourcing, Sept/Oct, pp.1-5
206 Combes, R.D. et al (2003) “Early microdose drug studies in human volunteers can minimise animal testing; Proceedings of a workshop organised by volunteers in research and testing”, European Journal of Pharmaceutical Sciences, vol.19, pp.1-11
207 http://www.netsci.org/Science/Compchem/feature
12.html
208 ADI, 2005, Keep animals out of REACH
209 http://wwww.lhasalimited.org/index.php?cat=2
&sub_cat=64
210 VITROCELLOMICS: Reducing animal experimentation in preclinical predictive drug testing be human hepatic in vitro models derived from embryonic stem cells. In: Genomics & Biotechnology for Health. Alternative Testing Strategies. European Commission, EU-Supported Research 2002-2006
211 http://er-projects.gf.liu.se/~vitrocellomics
212 Bi, Y-A. et al (2006) “Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport”, Drug metabolism and Disposition, vol.34, no.9, pp.1658-1665
213 Orr, S (2002) “UKHTB General Information
214 Lazarovici, P et al Intelligent Biomatrices and engineered Tissue Constructs: In vitro Models For Drug Discovery and Toxicity Testing in: ”Marx, U and Sandig, V(Eds) (2007) Drug Testing In Vitro: Breakthroughs and Trends in Cell Culture Technology. WILEY-VCH, Weinheim
215 World intellectual property organization (2005) http://www.wipo.int/pctdb/en/wo.jsp?wo=2005104755&IA=WO2005104755&DISPLAY=DESC
216 http://www.htscreening.org/
217 “Biochip Mimics the Body to Reveal Toxicity of Industrial Compounds” http://news.rpi.edu/update.do?artcenterkey=2376
218 The National Academies Press, 2005, Communicating Toxicogenomics Information to Nonexperts: A Workshop Summary (2005)
219 http://www.antidote-europe.org/substances_gb.htm
220 ‘One Third of Primate Species on the Brink’, New Scientist, 1 November 2007
221 1997, Ch.4, Countryside Undercover, ‘It’s a dog’s life’; The Campaigner, July-Dec 1997, NAVS.

Watch our Save the Primates Video

You need Flash player 8+ and JavaScript enabled to view this video.